Stock MRUS MERUS N.V.
Add to a list
To use this feature you must be a member
Log inSign up

Merus N.V. Share Price

Equities

MRUS

NL0011606264

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 21:00:00 26/04/2024 BST 		5-day change 1st Jan Change
45.04 USD +0.24% Intraday chart for Merus N.V. +13.14% +63.78%
04-19 Gilead Sciences Likely to Record IPR&D Hit on Q1 Non-GAAP Earnings, Oppenheimer Says MT
03-28 Truist Securities Initiates Coverage on Merus With Buy Rating, $69 Price Target MT

Financials

Sales 2024 * 38.33M 3.07B Sales 2025 * 54.99M 4.4B Capitalization 2.64B 212B
Net income 2024 * -191M -15.29B Net income 2025 * -222M -17.77B EV / Sales 2024 * 69 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 48.1 x
P/E ratio 2024 *
-13.9 x
P/E ratio 2025 *
-13 x
Employees 201
Yield 2024 *
-
Yield 2025 *
-
Free-Float 92.53%
More Fundamentals * Assessed data

Chart Merus N.V.

Dynamic Chart

Latest news about Merus N.V.

Gilead Sciences Likely to Record IPR&D Hit on Q1 Non-GAAP Earnings, Oppenheimer Says MT
Truist Securities Initiates Coverage on Merus With Buy Rating, $69 Price Target MT
Needham Raises Price Target on Merus to $66 From $65, Maintains Buy Rating MT
Gilead Sciences, Merus Collaborate to Discover New Potential Cancer Therapies MT
Gilead, Merus to Collaborate on Trispecific Antibody Research DJ
Gilead Sciences, Inc. and Merus N.V. Announce Collaboration to Discover Novel Antibody-Based Trispecific T-Cell Engagers CI
Merus N.V. announced that it has received $25.000035 million in funding from Gilead Sciences, Inc. CI
Needham Raises Price Target on Merus to $65 From $42, Keeps Buy Rating MT
Merus Full-Year 2023 Net Loss Widens, Revenue Increases MT
Earnings Flash (MRUS) MERUS N.V. Posts 2023 Revenue $43.95M MT
Merus N.V. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Merus Power Lands EUR15 Million Order for Battery Energy Storage System MT
Earnings Flash (MRUS) MERUS N.V. Reports Q3 Revenue $11M MT
Merus N.V. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Stifel Adjusts Merus' Price Target to $40 From $45, Maintains Buy Rating MT
More news

Analyst Recommendations on Merus N.V.

Truist Securities Initiates Coverage on Merus With Buy Rating, $69 Price Target MT
Needham Raises Price Target on Merus to $66 From $65, Maintains Buy Rating MT
Needham Raises Price Target on Merus to $65 From $42, Keeps Buy Rating MT
Stifel Adjusts Merus' Price Target to $40 From $45, Maintains Buy Rating MT
TD Cowen Starts Merus With Outperform Rating MT
More recommendations

Press releases Merus N.V.

Merus Announces Abstracts Accepted for Presentation at the 2024 ASCO Annual Meeting GL
Merus Presents Preclinical Data Demonstrating Efficacy of Zeno in Cancer Models with High NRG1 Expression at the AACR Annual Meeting 2024 GL
Merus Presents Preclinical Data Demonstrating Efficacy of Zeno in Cancer Models with High NRG1 Expression at the AACR Annual Meeting 2024 AQ
Merus to Participate in a Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference GL
Merus to Participate in a Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference AQ
More press releases

News in other languages on Merus N.V.

GNW-Adhoc: Merus gibt Annahme von Abstracts zur Präsentation auf der ASCO-Jahrestagung 2024 bekannt
Merus annonce les résumés acceptés pour présentation à la réunion annuelle 2024 de l’ASCO
Merus gibt Annahme von Abstracts zur Präsentation auf der ASCO-Jahrestagung 2024 bekannt
GNW-Adhoc: Merus stellt auf der AACR-Jahrestagung 2024 präklinische Daten als Beleg für die Wirksamkeit von Zeno in Krebsmodellen mit hoher NRG1-Expression vor
Merus présente des données précliniques démontrant l’efficacité de Zeno dans le traitement des modèles de cancer avec une forte expression du gène NRG1 lors de la réunion annuelle 2024 de l’AACR
More news

Quotes and Performance

1 day+0.24%
1 week+13.14%
Current month+0.02%
1 month+0.29%
3 months+32.31%
6 months+119.60%
Current year+63.78%
More quotes

Highs and lows

1 week
39.93
Extreme 39.93
45.84
1 month
39.27
Extreme 39.27
46.42
Current year
27.11
Extreme 27.11
52.04
1 year
18.21
Extreme 18.21
52.04
3 years
12.03
Extreme 12.03
52.04
5 years
10.18
Extreme 10.18
52.04
10 years
7.26
Extreme 7.255
52.04
More quotes

Managers and Directors - Merus N.V.

Managers TitleAgeSince
Bill Lundberg CEO
 Chief Executive Officer 60 11/06/19
Gregory Perry DFI
 Director of Finance/CFO 63 30/04/16
Ernesto Wasserman CTO
 Chief Tech/Sci/R&D Officer - 30/11/16
Members of the board TitleAgeSince
Gregory Perry DFI
 Director of Finance/CFO 63 30/04/16
Maxine Gowen BRD
 Director/Board Member 66 27/05/21
Paolo Pucci BRD
 Director/Board Member 63 29/06/20
More insiders

ETFs positioned on Merus N.V.

Name Weight AuM 1st Jan change Investor Rating
BMO MSCI GENOMIC INNOVATION INDEX ETF - CAD ETF BMO MSCI Genomic Innovation Index ETF - CAD
0.11% 2 M€ -.--%
LEVERAGE SHARES -3X SHORT BIOTECHNOLOGY ETP SECURITIES - USD ETF Leverage Shares -3x Short Biotechnology ETP Securities - USD
0.07% 0 M€ 0.00% -
LEVERAGE SHARES 3X LONG BIOTECHNOLOGY ETP SECURITIES - USD ETF Leverage Shares 3x Long Biotechnology ETP Securities - USD
0.06% 0 M€ 0.00% -
BMO MSCI INNOVATION INDEX ETF - CAD ETF BMO MSCI Innovation Index ETF - CAD
0.04% 7 M€ -.--% -
More ETFs positioned on Merus N.V.

Quotes

Date Price Change Volume
26/04/24 45.04 +0.24% 822,968
25/04/24 44.93 +7.05% 1,921,425
24/04/24 41.97 +2.82% 741,293
23/04/24 40.82 +0.91% 572,348
22/04/24 40.45 +1.61% 705,458

Delayed Quote Nasdaq, April 26, 2024 at 09:00 pm

More quotes

Company Profile

Merus NV is the Netherlands - based biotechnology company, concentrated on developing differentiating therapeutics for cancer patients. The product programs in the Merus pipeline are based on the Multiclonics format. Its products are designed to bind to multiple targets, and are manufactured with features for anti-cancer effects against the complex mechanisms that drive cancer. Company's products engage cancer antigens and harness the power of the immune system to kill tumor cells by utilizing technology platform. One of the drug zenocutuzumab (Zeno), a Biclonics antibody, concentrates on helping patients with lung, pancreatic and other types of solid tumors. The company operates in the Netherlands and United States.
Sector
Biotechnology & Medical Research
Calendar
05/05/2024 - Q1 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Ratings for Merus N.V.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
45.04 USD
Average target price
60.45 USD
Spread / Average Target
+34.22%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
MERUS N.V. Stock Merus N.V.
+63.78% 2.64B
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.31% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.56% 95.28B
ARGENX SE Stock argenx SE
+1.69% 22.15B
BIONTECH SE Stock BioNTech SE
-17.37% 21.02B
GENMAB A/S Stock Genmab A/S
-9.30% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.74B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.85% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.21% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.54% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. MRUS Stock